These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36735530)

  • 61. Impact of Immune-Related Adverse Events on Immune Checkpoint Inhibitors Treated Cancer Patients' Survival: Single Center Experience and Literature Review.
    Romão R; Mendes AS; Ranchor R; Ramos MJ; Coelho J; Pichel RC; Azevedo SX; Fidalgo P; Araújo A
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765845
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey.
    Ghosh N; Tirpack A; Chan KK; Bass AR
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067320
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
    Das S; Ciombor KK; Haraldsdottir S; Pumpalova Y; Sahin IH; Pineda G; Shyr Y; Lin EP; Hsu CY; Chu SK; Goff LW; Cardin DB; Bilen MA; Fisher GA; Wu C; Berlin J
    Oncologist; 2020 Aug; 25(8):669-679. PubMed ID: 31943525
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy.
    Lusa A; Alvarez C; Saxena Beem S; Schwartz TA; Ishizawar R
    BMC Rheumatol; 2022 Nov; 6(1):64. PubMed ID: 36345032
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
    Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
    Front Immunol; 2021; 12():730320. PubMed ID: 34646270
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pneumatosis intestinalis in cancer patients who received immune checkpoint inhibitors.
    Sperling G; Shatila M; Varatharajalu K; Lu Y; Altan M; Zhou Y; Zhao D; De Toni EN; Török HP; Schneider BJ; Khan A; Thomas AS; Zhang HC; Shafi MA; Wang Y
    J Cancer Res Clin Oncol; 2023 Dec; 149(19):17597-17605. PubMed ID: 37917197
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors.
    Maillet D; Corbaux P; Stelmes JJ; Dalle S; Locatelli-Sanchez M; Perier-Muzet M; Duruisseaux M; Kiakouama-Maleka L; Freyer G; Boespflug A; Péron J
    Eur J Cancer; 2020 Jun; 132():61-70. PubMed ID: 32334337
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Management and outcome of oncological patients under immune checkpoint inhibitors presenting at the emergency department.
    Pini F; Grigoriu B; Lieveke A; Meert AP
    Emerg Med J; 2024 Jun; 41(7):417-421. PubMed ID: 38688713
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune-Related Adverse Events.
    Guo M; VanderWalde AM; Yu X; Vidal GA; Tian GG
    Clin Lung Cancer; 2022 Dec; 23(8):686-693. PubMed ID: 36050243
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
    Tison A; Quéré G; Misery L; Funck-Brentano E; Danlos FX; Routier E; Robert C; Loriot Y; Lambotte O; Bonniaud B; Scalbert C; Maanaoui S; Lesimple T; Martinez S; Marcq M; Chouaid C; Dubos C; Brunet-Possenti F; Stavris C; Chiche L; Beneton N; Mansard S; Guisier F; Doubre H; Skowron F; Aubin F; Zehou O; Roge C; Lambert M; Pham-Ledard A; Beylot-Barry M; Veillon R; Kramkimel N; Giacchero D; De Quatrebarbes J; Michel C; Auliac JB; Gonzales G; Decroisette C; Le Garff G; Carpiuc I; Vallerand H; Nowak E; Cornec D; Kostine M;
    Arthritis Rheumatol; 2019 Dec; 71(12):2100-2111. PubMed ID: 31379105
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors.
    Foster CC; Couey MA; Kochanny SE; Khattri A; Acharya RK; Tan YC; Brisson RJ; Leidner RS; Seiwert TY
    Cancer; 2021 Dec; 127(24):4565-4573. PubMed ID: 34547103
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: Unraveling the complexities at the intersection of immunology and vascular pathology.
    Lee CM; Wang M; Rajkumar A; Calabrese C; Calabrese L
    Semin Arthritis Rheum; 2024 Jun; 66():152440. PubMed ID: 38579593
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical impact of venous thromboembolism in non-small cell lung cancer patients receiving immunotherapy.
    Bjørnhart B; Kristiansen C; Asmussen J; Hansen KH; Wedervang K; Jørgensen TL; Herrstedt J; Schytte T
    Thromb Res; 2023 Jan; 221():164-172. PubMed ID: 36396518
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Hematological immune related adverse events after treatment with immune checkpoint inhibitors.
    Kramer R; Zaremba A; Moreira A; Ugurel S; Johnson DB; Hassel JC; Salzmann M; Gesierich A; Weppler A; Spain L; Loquai C; Dudda M; Pföhler C; Hepner A; Long GV; Menzies AM; Carlino MS; Sachse MM; Lebbé C; Baroudjian B; Enokida T; Tahara M; Schlaak M; Hayani K; Bröckelmann PJ; Meier F; Reinhardt L; Friedlander P; Eigentler T; Kähler KC; Berking C; Zimmer L; Heinzerling L
    Eur J Cancer; 2021 Apr; 147():170-181. PubMed ID: 33706206
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer.
    Issa M; Tang J; Guo Y; Coss C; Mace TA; Bischof J; Phelps M; Presley CJ; Owen DH
    Expert Rev Anticancer Ther; 2022 Aug; 22(8):861-874. PubMed ID: 35786142
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
    Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
    J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 78. An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive Analysis.
    Liang KL; Tackett S; Myers S; Brahmer JR; Browner IS; Ettinger DS; Forde PM; Hales RK; Hann CL; Lam VK; Marrone KA; Patel T; Peterson V; Sagorsky S; Turner M; Voong KR; Naidoo J; Feliciano JL
    Curr Oncol; 2022 Jun; 29(6):4342-4353. PubMed ID: 35735456
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis.
    Bastacky ML; Wang H; Fortman D; Rahman Z; Mascara GP; Brenner T; Najjar YG; Luke JJ; Kirkwood JM; Zarour HM; Davar D
    Front Oncol; 2021; 11():749064. PubMed ID: 34900695
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer.
    Jacob JS; Dutra BE; Garcia-Rodriguez V; Panneerselvam K; Abraham FO; Zou F; Ma W; Grivas P; Thompson JA; Altan M; Oliva ICG; Zhang HC; Thomas AS; Wang Y
    J Natl Compr Canc Netw; 2021 Aug; 19(12):1415-1424. PubMed ID: 34348238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.